David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 21,182 shares at $232.68 ($4.9M) on 2022-02-25, disclosed to the SEC on 2022-02-28.
Seasonal sale ($4.9M) by EVP, Global Research and CSO — this insider has traded VRTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $227.86 | 6,038 | $1.4M | 28.2% |
| 2 | $229.41 | 1,040 | $239K | 4.9% |
| 3 | $229.41 | 1,040 | $239K | 4.9% |
| 4 | $230.62 | 3,188 | $735K | 15.1% |
| 5 | $230.62 | 3,188 | $735K | 15.1% |
| 6 | $231.64 | 2,784 |
| $645K |
| 13.2% |
| 7 | $231.64 | 2,784 | $645K | 13.2% |
| 8 | $232.68 | 560 | $130K | 2.7% |
| 9 | $232.68 | 560 | $130K | 2.7% |
| Total | $230.09 avg | 21,182 | $4.9M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |